219 results about "Adenocarcinoma lung cancer" patented technology

The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.

Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment.

The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medullablastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The invention relates to the technical field of biology, and in particular relates to a group of LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer, related kits and application thereof. The group of LncRNA biomarkers for diagnosing human lung adenocarcinoma and / or human colorectal cancer comprises uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174. The LncRNA biomarkers for diagnosing the human lung adenocarcinoma and / or human colorectal cancer can be used for distinguishing human early lung adenocarcinoma and human colorectal cancer, the AUC of the biomarkers for distinguishing early lung adenocarcinoma from normally paired lung tissues can reach 0.978, and the sensitivity and the specificity are respectively 92% and 98%. The AUC of the biomarkers for diagnosing a colorectal cancer sample can reach 0.963, and the sensitivity and the specificity are respectively 94.4% and 88.9%.

The invention belongs to the technical field of lung adenocarcinoma prediction, and specifically relates to an identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and a constructing method of a risk prediction model. The constructing method includes the steps of: data remodeling and grouping, data standardization, phase specific gene extraction, geneco-expression correlation analysis, unsupervised cluster analysis, specific and non-specific co-expression network analysis, functional pathway gathering, significant variation pathway identification, screening of early screening marker genes by using an REE algorithm, establishment of a classification model based on early screening risk genes, survival analysis verification, and the like. The identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and the constructing method of a risk prediction model can realize the early diagnosis of lung cancer,and can identify gene markers which change significantly with the progress of lung cancer at the same time.

Macrophages within the tumor microenvironment, also called tumor associated macrophages (TAMs) have been shown to play a major role in the growth and spread of many types of cancer. Cancer cells produce cytokines that cause the macrophages to differentiate into an M2 subtype. We have designed a mannosylated liposome (MAN-LIPs) and successfully showed it to accumulate in TAMs in a mouse model of pulmonary adenocarcinoma. These liposomes are loaded with 64Cu to allow tracking by PET imaging, and contain a fluorescent dye in the lipid bilayer permitting subsequent fluorescence microscopy. MAN-LIPs are a promising new vehicle for the delivery of imaging agents to lung TAMs. In addition to imaging, they hold the potential for delivery of therapeutic agents to the tumor microenvironment.

The invention relates to an EML4-ALK (echinoderm microtubule associated protein like4-anaplastic lymphoma kinase) fusion gene fluorescent quantitative PCR (polymerase chain reaction) assay kit, which is applicable to assay of EML4-ALK fusion gene mutation in lung adenocarcinoma. The kit comprises probes, primers and positive controls, which are specially designed for conserved sequences of 9 fusion variations of the EML4-ALK fusion gene. The kit can be used for quickly and accurately assaying 9 most common EML4-ALK fusion gene variations with high sensitivity, namely 9 fusion variations of 7 variant subtypes, which are subtype 1 (E13; A20), subtype 2 (E20; A20), subtype 3 (E6a / b; A20), subtype 4 (E14; A20), subtype 5 (E2a / b; A20), subtype 6 (E18; A20) and subtype 7 (E14; A20), so that a real-time fluorescent quantitative PCR system for assaying 9 most common EML4-ALK fusion gene variations can be established.

The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.

The invention relates to a 1-substituted-4, 4-bis-substituted thiosemicarbazide compound, a relative preparation method and application thereof, wherein the compound is represented as formula I, R1, R2 and R3 are defined as description. The inventive compound can restrain A-549 (human lung adenocarcinoma), P388 (mouse leukemia cell line), and HT-29 (human intestinal cancer cell line), with strong inhibition of cell proliferation, which can be used to develop new anti-cancer drug.

The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e. cell cycle and apoptosis, cell growth, extracellular signaling, angiogenesis and invasion, is identified, whose expression is significantly changed. In particular, the expression pattern found uncovers the network of molecules leading to mammalian papillary adenocarcinomas of the lung.

The invention discloses a prognosis marker for the lung cancer and application thereof. The long chain non-coding RNA gene RP11-434D9.1 of the marker is quite related to the prognosis period of patients with the lung cancer, through the marker and expression for detecting the marker, lung cancer prognosis is rapidly, accurately and conveniently predicted, the grading and layering of lung cancer risks are realized according to molecular levels, and patients with different grades of risks are separated obviously. Through co-expression analysis, 238 genes related to the long chain non-coding RP1-434D9.1 are found out, through an enrichment analysis on GO and KEGG pathways of the 238 genes, the molecular functions of the long-chain non-coding RP1-434D9.1 are found out, and important biologicalexperiment clues are provided for improving prognosis molecular diagnosis of the patients with the lung cancer and related medicine targets.

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549 / DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

The invention discloses an HoxC11 gene or HoxC11 gene which can be used for preparing a lung adenocarcinoma pre-diagnostic reagent and a kit and preparing lung adenocarcinoma pre-diagnostic prognosis evaluation reagents or treatment drugs. Reverse transcription is performed after RNA is extracted from a normal lung tissue sample of lung adenocarcinoma, expression of HoxC11 is detected through a real-time fluorescence quantification method, and a result shows that HoxC11 can be highly expressed in lung adenocarcinoma tissue. It is promoted that HoxC11 can be used as a lung adenocarcinoma pre-diagnostic molecular marker. The powerful molecular biology tool is provided for lung adenocarcinoma auxiliary diagnosis and prognosis prediction, and the profound clinic significance and significant application and popularization prospects are achieved.

The invention discloses a marker for diagnosing and treating lung adenocarcinoma. The PLD5 gene is highly expressed in lung adenocarcinoma tissues, the inhibition of the expression of the PLD5 gene can promote the apoptosis of lung adenocarcinoma cells. The expression level of the PLD5 gene in the lung tissues can be detected to sensitively and specifically diagnose lung adenocarcinoma. The invention also provides a treatment means for lung adenocarcinoma.

The present invention relates to markers and diagnostic reagents for the diagnosis or prognosis of lung cancer. The present invention discloses for the first time that DDX56 is significantly increasedin patients with early disease progression (= 12 months) after treatment of two major subtypes of small cell lung cancer (lung squamous cell carcinoma, lung adenocarcinoma), and that the increased expression of DDX56 significantly affects the overall survival of the patients. Therefore, DDX56 can be used as a diagnostic marker for early recurrence of lung squamous cell carcinoma or lung adenocarcinoma.

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.

The invention discloses application of a biomarker as a target to the diagnosis and the treatment of lung adenocarcinoma. Particularly, the biomarker is CLINT1. The worldwide incidence rate of the lung adenocarcinoma continuously increases; an effective biomarker is needed to diagnose and / or treat the lung adenocarcinoma. The application is proven through an experiment; the expression, in a patient suffered from the lung adenocarcinoma, of the CLINT1 is up-regulated; the multiplication and the invasion of a lung adenocarcinoma cell can be inhibited by decreasing the expression of a CLINT1 gene. Prompted, the CLINT1 disclosed by the invention can be used as a marker for the early diagnosis of the lung adenocarcinoma; meanwhile, the gene can be also used as a potential drug target spot for treating the lung adenocarcinoma; the foundation is provided for the accurate medical treatment of the lung adenocarcinoma.

In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.

The invention provides microRNA (micro ribonucleic acid) for identification of subtypes of a lung cancer. The miroRNA is chosen from the following sequence: a) a sequence shown as SEQ ID No. n (sequence identification number), or b) microRNA complementary to the sequence shown as SEQ ID No. n, wherein the n is 2, 3, 4 or 7. The invention further provides an application of the microRNA and a reagent kit based on the microRNA. The invention further provides a set formed by the microRNA, an application of the set and a reagent kit based on the set. The miroRNA has the advantages that the microRNA can form two combinations, namely SEQ ID No.2 and SEQ ID No.7, as well as SEQ ID No.3 and SEQ ID No.4, which can be used to differentially diagnose the small cell lung cancer, non-small cell lung cancer, adenocarcinoma lung cancer and squamous cell lung cancer respectively; the diagnosis is high in speed, low in cost and accurate and reliable in result; and a significant basis is provided for performing precise targeted therapy on a patient with the lung cancer.

The invention discloses a traditional Chinese medicinal composition for treating lung cancer and liver cancer. The composition consists of rhizoma paridis yunnanensis extract, rhizoma curcumae longae extract and white paeony root extract according to a mass ratio of 1:(15-25):(5-15). Experiments prove that the traditional Chinese medicinal composition can obviously inhibit lung cancer cell lines such as LA795 and hepatoma cell lines such as Hep-B3 from growing, the half maximal inhibitory concentrations (IC50) of the lung cancer cell lines and the hepatoma cell lines can respectively reach below 20 micrograms / milliliter; tests on mouse models bearing lung adenocarcinoma and liver cancer tumors show that the lung adenocarcinoma and liver cancer inhibition rates are respectively above 50%, and the spleen index and liver index of mice are increased; and compared with raw medicinal materials which are separately applied, the medicinal composition has high anti-lung cancer and anti-liver cancer activities, an exact effect and a good inhibition effect on lung cancer and liver cancer.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

The invention discloses a mark used for prediction of prognosis of a lung adenocarcinoma. The mark is composed of OPN3, GALNT2, FAM83A AND KYUN, and a mathematical model for prediction of prognosis ofthe lung adenocarcinoma is established based on the four indexes of OPN3, GALNT2, FAM83A AND KYUN, wherein the expression formula of the mathematical model is P=0.0004A+0.0042B+0.0055C+0.0077D, in the formula, P is a risk coefficient, A is the expression quantity of OPN3, B is the expression quantity of GALANT2, C is the expression quantity of FAM83A, and D is the expression quantity of KYNU. When P is higher than 0.216, it is defined to have a high risk, and otherwise it is defined to have a low risk. The prediction for AUC of the prognosis of the lung adenocarcinoma reaches 0.71 through themodel, when cut-off is 0.216, the sensitiveness of predicting a three-year overall life cycle of a patient with the lung adenocarcinoma is 53.3% through the mode, specificity is 82.9%, the average overall life cycle of patient groups with high risks of the lung adenocarcinoma is about 46 months, and the average overall life cycle of patient groups with low risks is about 94 months.

The invention belongs to the technical field of medicaments, and discloses anti-tumor medicaments of S-(bromo-acetamido-alanyl-methyl) glutathione and S-(bromo-acetamido-butaminoacyl-methyl) glutathione. The compound reacts with aldoketomutase I in a covalent bond mode so that the aldoketomutase I losses the activity irreversibly. The compound has good development and application prospects in theaspects of medicaments for treating the malignant tumors of prostate cancer, lung cancer, intestinal cancer, testicular cancer, leukemia, mammary cancer, skin cancer and the like.

Phylogenin C and its derivatives and their application in the preparation of anticancer drugs, the general formula of phyloganin C and its derivatives is: wherein, R=H, CH3, (CH2)3Cl, CH2CCH, SO2Ph, CH2Ph , CH2COOCH3, etc., phyloganin C and its derivatives of the present invention have significant inhibitory effects on various tumor cell lines such as lung cancer, lung adenocarcinoma, liver cancer, breast cancer, uterine cancer, etc., and have significant inhibitory effects on normal cells. It can be prepared as a medicine for treating cancer in the form of injection, tablet capsule, suspension or emulsion.

An immune-proteomic screening of AAb responses using protein arrays has identified two panels of Aab (antigen / antibody complexes) that can potentially differentiate lung adenocarcinoma from smoker controls as well as CT positive benign lung disease. The resulting biomarkers appear to have high specificity so that high risk subjects with a positive CT screen and a positive serum test should get more invasive test such as needle biopsy for a timely cancer diagnosis, among other advantages.

The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.

Certain cells, including cancer cells such as cells from cancers of the colon, breast, lung, ovary, prostate, pancreas and skin are capable of expressing BCLP. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of the cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of tumors that express BCLP are described.